Tags

Type your tag names separated by a space and hit enter

Alcoholic liver disease: pathogenesis, management, and novel targets for therapy.
J Gastroenterol Hepatol 2013; 28 Suppl 1:77-84JG

Abstract

Alcohol use is a leading cause of preventable morbidity and mortality worldwide, with much of its negative impact as the result of alcoholic liver disease (ALD). ALD is a broad term that encompasses a spectrum of phenotypes ranging from simple steatosis to steatohepatitis, progressive fibrosis, cirrhosis, and hepatocellular carcinoma. The mechanisms underlying the development of these different disease stages are incompletely understood. Standard treatment of ALD, which includes abstinence, nutritional support, and corticosteroids, has not changed in the last 40 years despite continued poor outcomes. Novel therapies are therefore urgently needed. The development of such therapies has been hindered by inadequate resources for research and unsuitable animal models. However, recent developments in translational research have allowed for identification of new potential targets for therapy. These targets include: (i) CXC chemokines, (ii) IL-22/STAT3, (iii) TNF receptor superfamily, (iv) osteopontin, (v) gut microbiota and lipopolysaccharide (LPS), (vi) endocannabinoids, and (vii) inflammasomes. We review the natural history, risk factors, pathogenesis, and current treatments for ALD. We further discuss the findings of recent translational studies and potential therapeutic targets.

Authors+Show Affiliations

Department of Medicine, Division of Gastroenterology and Hepatology, University of North Carolina, Chapel Hill, North Carolina 27599, USA. ramon_bataller@med.unc.eduNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, N.I.H., Extramural
Review

Language

eng

PubMed ID

23855300

Citation

Orman, Eric S., et al. "Alcoholic Liver Disease: Pathogenesis, Management, and Novel Targets for Therapy." Journal of Gastroenterology and Hepatology, vol. 28 Suppl 1, 2013, pp. 77-84.
Orman ES, Odena G, Bataller R. Alcoholic liver disease: pathogenesis, management, and novel targets for therapy. J Gastroenterol Hepatol. 2013;28 Suppl 1:77-84.
Orman, E. S., Odena, G., & Bataller, R. (2013). Alcoholic liver disease: pathogenesis, management, and novel targets for therapy. Journal of Gastroenterology and Hepatology, 28 Suppl 1, pp. 77-84. doi:10.1111/jgh.12030.
Orman ES, Odena G, Bataller R. Alcoholic Liver Disease: Pathogenesis, Management, and Novel Targets for Therapy. J Gastroenterol Hepatol. 2013;28 Suppl 1:77-84. PubMed PMID: 23855300.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Alcoholic liver disease: pathogenesis, management, and novel targets for therapy. AU - Orman,Eric S, AU - Odena,Gemma, AU - Bataller,Ramon, PY - 2013/04/20/accepted PY - 2013/7/17/entrez PY - 2013/7/24/pubmed PY - 2014/3/26/medline KW - alcoholic liver diseases KW - fibrosis KW - inflammation KW - translational research SP - 77 EP - 84 JF - Journal of gastroenterology and hepatology JO - J. Gastroenterol. Hepatol. VL - 28 Suppl 1 N2 - Alcohol use is a leading cause of preventable morbidity and mortality worldwide, with much of its negative impact as the result of alcoholic liver disease (ALD). ALD is a broad term that encompasses a spectrum of phenotypes ranging from simple steatosis to steatohepatitis, progressive fibrosis, cirrhosis, and hepatocellular carcinoma. The mechanisms underlying the development of these different disease stages are incompletely understood. Standard treatment of ALD, which includes abstinence, nutritional support, and corticosteroids, has not changed in the last 40 years despite continued poor outcomes. Novel therapies are therefore urgently needed. The development of such therapies has been hindered by inadequate resources for research and unsuitable animal models. However, recent developments in translational research have allowed for identification of new potential targets for therapy. These targets include: (i) CXC chemokines, (ii) IL-22/STAT3, (iii) TNF receptor superfamily, (iv) osteopontin, (v) gut microbiota and lipopolysaccharide (LPS), (vi) endocannabinoids, and (vii) inflammasomes. We review the natural history, risk factors, pathogenesis, and current treatments for ALD. We further discuss the findings of recent translational studies and potential therapeutic targets. SN - 1440-1746 UR - https://www.unboundmedicine.com/medline/citation/23855300/Alcoholic_liver_disease:_pathogenesis_management_and_novel_targets_for_therapy_ L2 - https://doi.org/10.1111/jgh.12030 DB - PRIME DP - Unbound Medicine ER -